Compare MGTX & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGTX | STAA |
|---|---|---|
| Founded | 2015 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2018 | 1995 |
| Metric | MGTX | STAA |
|---|---|---|
| Price | $10.89 | $22.46 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 12 |
| Target Price | ★ $27.75 | $27.70 |
| AVG Volume (30 Days) | ★ 932.9K | 845.1K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.02 | N/A |
| EPS | ★ 1.30 | 0.26 |
| Revenue | $81,391,000.00 | ★ $239,442,000.00 |
| Revenue This Year | $314.19 | $39.61 |
| Revenue Next Year | N/A | $7.86 |
| P/E Ratio | ★ $8.40 | $86.81 |
| Revenue Growth | ★ 144.57 | N/A |
| 52 Week Low | $6.62 | $15.59 |
| 52 Week High | $15.35 | $35.87 |
| Indicator | MGTX | STAA |
|---|---|---|
| Relative Strength Index (RSI) | 31.37 | 50.99 |
| Support Level | $8.84 | $21.72 |
| Resistance Level | $11.85 | $24.31 |
| Average True Range (ATR) | 0.58 | 0.90 |
| MACD | -0.18 | 0.26 |
| Stochastic Oscillator | 13.29 | 82.91 |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.